Aspire Biopharma Holdings, Inc. WarrantASBPW
About: Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1% more capital invested
Capital invested by funds: $625K [Q4 2024] → $630K (+$5.21K) [Q1 2025]
0% more funds holding
Funds holding: 26 [Q4 2024] → 26 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for ASBPW.
Financial journalist opinion
We haven’t received any recent news articles for ASBPW.